MQS Management LLC purchased a new position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 2,617 shares of the company’s stock, valued at approximately $443,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Natixis Investment Managers International boosted its stake in Zoetis by 19.1% during the 1st quarter. Natixis Investment Managers International now owns 219,243 shares of the company’s stock valued at $37,098,000 after acquiring an additional 35,220 shares during the last quarter. Natixis increased its position in shares of Zoetis by 282.6% in the 1st quarter. Natixis now owns 217,374 shares of the company’s stock worth $36,782,000 after purchasing an additional 160,562 shares during the last quarter. Platinum Investment Management Ltd. acquired a new stake in shares of Zoetis in the 1st quarter valued at about $3,384,000. Tiemann Investment Advisors LLC lifted its position in shares of Zoetis by 13.7% during the first quarter. Tiemann Investment Advisors LLC now owns 1,620 shares of the company’s stock worth $274,000 after purchasing an additional 195 shares during the last quarter. Finally, Pitcairn Co. grew its stake in Zoetis by 7.8% in the first quarter. Pitcairn Co. now owns 34,825 shares of the company’s stock worth $5,893,000 after purchasing an additional 2,507 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.
Zoetis Price Performance
Shares of ZTS traded up $1.10 during midday trading on Thursday, reaching $180.76. The stock had a trading volume of 2,445,077 shares, compared to its average volume of 2,829,597. The firm’s 50 day moving average price is $174.40 and its 200-day moving average price is $176.41. The company has a market capitalization of $82.48 billion, a P/E ratio of 34.83, a P/E/G ratio of 2.79 and a beta of 0.86. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94.
Zoetis Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date is Thursday, July 18th. Zoetis’s payout ratio is 33.33%.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. The Goldman Sachs Group decreased their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. Barclays lowered their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. HSBC dropped their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Finally, BTIG Research initiated coverage on shares of Zoetis in a report on Thursday. They set a “buy” rating and a $220.00 price target for the company. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average price target of $212.67.
Read Our Latest Research Report on ZTS
Zoetis Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- What Are Growth Stocks and Investing in Them
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- 3 Tickers Leading a Meme Stock Revival
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- What Makes a Stock a Good Dividend Stock?
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.